Business Wire

 Ricardo Defense awarded a sole-source contract valued at over $89M to deliver 9,480 ABS/ESC retrofit kits to US Army

17.3.2021 10:00:00 EET | Business Wire | Press release

Share

The Army today awarded Ricardo Defense a base contract to provide up to 9,480 critical safety improvement Antilock Brake System / Electronic Stability Control (ABS/ESC) retrofit kits over the next three years for the U.S. Army’s High Mobility Multipurpose Wheeled Vehicle (HMMWV). The first delivery order, under the three-year base contract, will include $10M to deliver 1,200 ABS/ESC retrofit kits by August 2021. A second delivery order is expected later this year to increase deliveries to approximately 2,000 ABS/ESC retrofit kits over the next 12 months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005179/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

High Mobility Multipurpose Wheeled Vehicle (HMMWV) (Photo: Business Wire)

Historical data presented by the National Highway Traffic Safety Administration (NHTSA) indicates that the application of ABS and ESC reduces the number of fatal rollovers by 74%, and fatal impacts by 45%. Today’s initial award marks the beginning of a multi-year contract for Ricardo Defense to improve the safety and operational readiness of the fielded HMMWV fleet for U.S. soldiers and HMMWV operators worldwide.

Chet Gryczan, president of Ricardo Defense said: “This is a significant milestone and strong example of Ricardo Defense’s commitment to provide solutions to meet the tough challenges facing our customers and ensure the safety of our men and women in uniform. In fielding this system, we are tremendously proud to contribute to the Army’s commitment to the safety of our soldiers and civilians alike.”

The HMMWV is projected to remain in the U.S. Army’s fleet until 2050. In 2018, the Army mandated that all new HMMWVs coming off the new vehicle production line must have the ABS/ESC system installed. Since July 2018, more than 5,000 new production or Recapitalized HMMWV vehicles have been delivered to the US Army with Ricardo’s ABS/ESC technology. In 2019, the Army provisioned Ricardo’s ABS/ESC retrofit kit into the national stock system for retrofit of vehicles not addressed during new production or Recapitalization. This dual-approach ensures that all HMMWVs in the enduring fleet are eventually fit with the ABS/ESC rollover mitigation technology.

A spokesperson for the U.S. Army, Product Director Light Tactical Vehicles said, “The ABS/ESC retrofit contract award is a culmination of a lot of great work from all parties, and is an essential step in providing this critical safety solution to our fielded HMMWV fleet. We are extremely proud of the Army’s collaboration with Ricardo Defense to provide an affordable and attainable solution that significantly reduces loss of control incidents, vehicle rollover incidents, and ultimately helps save lives.”

Red River Army Depot, in partnership with Ricardo Defense, will complete ABS/ESC retrofit installations at the Army’s Center of Industrial and Technical Excellence for tactical wheeled vehicles in Texarkana, Texas and at regional sites across the U.S. beginning in March 2021.

ENDS

About Ricardo

Ricardo plc is a world-class environmental, engineering and strategic consulting company listed on the London Stock Exchange. With over 100 years of engineering excellence, we provide exceptional levels of expertise in delivering leading edge and innovative cross sector sustainable products and solutions, helping our global customers increase efficiencies, achieve growth and create a clear and safer future. Our mission is clear –- to create a world fit for the future. For more information visit www.ricardo.com

About Ricardo Defense, Inc

Ricardo Defense Inc. is a Ricardo subsidiary delivering high-value system engineering, mission critical software, vehicle builds, and safety-critical products to the US Department of Defense as well as governments and defense industry suppliers world-wide. Ricardo Defense is a recognized leader in the integration of complex systems and acquisition planning and system support services for major defense programs around the globe.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Ricardo:

Kate Caulfield
Ricardo Defense
Email: kathryn.caulfield@ricardodefense.com
Telephone: (586) 899-7668

Ricardo Media Office
Gill Gibbons
Email: media@ricardo.com
Telephone: +44 (0) 7795 342804

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye